CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 31.15×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
980.22MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.70xvs all stocks
52-Week Change
-55.88%vs all stocks
Market Capitalization
980.22MUSDvs all stocks (USD)
Enterprise Value
491.64MUSDvs all stocks (USD)
Forward P/E
-4.83xvs Biotechnology peers
Enterprise to EBITDA
-1.44xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-69.76%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-341.72MUSDvs all stocks (USD)
Net Income (TTM)
-883.08MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-149.89MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-188.83MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-371.64MUSDvs all stocks (USD)
Pre-tax Income
-695.98MUSDFY2025 · Dec 31, 2025Net Income
-695.98MUSDFY2025 · Dec 31, 2025EBIT
-371.64MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-34.40MUSDFY2025 · Dec 31, 2025Research & Development
321.53MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
50.11MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.87MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-695.98MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-158.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-158.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
396.65MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-695.98MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.89MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.91MUSDFY2025 · Dec 31, 2025Other Non-cash Items
518.02MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.41MUSDFY2025 · Dec 31, 2025Capital Expenditures
-142.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-53.66MUSDFY2025 · Dec 31, 2025Sale of Investments
5.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-48.80MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.32MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
326.88MUSDFY2025 · Dec 31, 2025Shares Outstanding
54.19MSharesUpdated Jul 19, 2026Float Shares
40.17MSharesUpdated Jul 19, 2026Shares Short
7.74MSharesUpdated Jul 19, 2026Short Ratio
5.41daysvs all stocks
Short % of Shares Outstanding
17.09%vs all stocks
% Held by Insiders
4.27%vs all stocks
% Held by Institutions
69.56%vs all stocks
Total Cash (MRQ)
491.52MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.07USDUpdated Jul 19, 2026Total Debt (MRQ)
2.94MUSDvs all stocks (USD)
Current Ratio (MRQ)
31.15xvs Biotechnology peers
Book Value per Share (MRQ)
-2.78USDUpdated Jul 19, 2026Total Assets
464.13MUSDvs all stocks (USD)
Total Current Assets
458.11MUSDFY2025 · Dec 31, 2025Total Liabilities
628.44MUSDFY2025 · Dec 31, 2025Total Non-current Assets
6.02MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
603.27MUSDFY2025 · Dec 31, 2025Total Current Liabilities
25.17MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
396.49MUSDFY2025 · Dec 31, 2025Other Short-term Investments
58.72MUSDFY2025 · Dec 31, 2025Accounts Payable
5.13MUSDFY2025 · Dec 31, 2025Short-term Debt
280.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
554.00KUSDFY2025 · Dec 31, 2025Long-term Debt
2.72MUSDFY2025 · Dec 31, 2025Common Stock (Book)
18.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.15BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-164.31MUSDvs all stocks (USD)
52-Week Low
6.50USDUpdated Jul 19, 202652-Week High
53.00USDUpdated Jul 19, 202652-Week Change
-55.88%vs all stocks
Beta
1.70xvs all stocks
50-Day MA
15.93USDUpdated Jul 19, 2026200-Day MA
16.34USDUpdated Jul 19, 2026Avg 10-Day Volume
1.35MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.56MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-70.40USDUpdated Jul 19, 2026Other Income / Expense
-330.21MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 31.15×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 31.15Industry median: 5.64Industry P95: 23.02Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Chongqing Pharscin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Janux Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Seegene, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hob Biotech Group Suzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Ruking Technology Co., Ltd.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
Zhejiang Sling Automobile Co., Ltd.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
Foci Fiber Optic Communications, Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated